# Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06425926/  
OnCo record `nct06425926` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GIM-531 in melanoma, run by Georgiamune Inc, now recruiting.

## Summary

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06425926 by Georgiamune Inc, with 117 participants planned, started 2024-05-09 and due to reach its primary completion in 2026-12. Interventions recorded: GIM-531 and Anti-PD-1 monoclonal antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06425926
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors
- Sponsor: Georgiamune Inc
- Enrolled: 117

## Sources

- ClinicalTrials.gov NCT06425926: https://clinicaltrials.gov/study/NCT06425926

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Georgiamune](https://onco.cc/companies/georgiamune/)

---
JSON: https://onco.cc/api/v1/entities/nct06425926.json